ClinicalTrials.gg
RecruitingNCT06694740INFINITYUpdated Nov 12, 2026

Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

A Phase 2/3 interventional study of Interferon Gamma 1-b and Placebo in Post-aggressive Immunosuppression, Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6 and Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Nov 12, 2026Eligibility revised5 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris — 14 open to participants now, 15 under way, 3 of them phase 3. Sepsis · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
14th of 23
170 · median 340
Started
2026
with 6 others
Phase 2/3
Only one
of the 35
Primary completion
2029-03
later than 13 of 14 live
Registered
28th of 35
by date

Among the 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris, this one is the 14th largest by planned enrollment of the 23 interventional ones that give a count, is one of 7 that started in 2026, is the only one in phase 2/3, reaches primary completion later than 13 of the 14 other live ones, and was the 28th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

14 of the 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).

Read the detailed description

The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).

This immunological adaptation, initially implemented as a host defense mechanism to protect against an overwhelming systemic reaction, can, if prolonged, lead to multiple complications resulting in significant delayed morbidity and mortality. Diagnosis is based on the use of immuno-inflammatory biomarkers, the most widely studied of which is monocyte expression of major histocompatibility complex type II molecules (mHLA-DR).

We have recently confirmed that PAIS can affect all types of patients admitted to the intensive care unit, but mainly occurs in the most severe patients. We also showed that the occurrence of PAIS was strongly associated with the subsequent occurrence of secondary infection and excess mortality.

Currently, there is no treatment with proven efficacy for PAIS, but several drugs have been shown to restore leukocyte function in-vitro. Several teams have reported the use of immunostimulatory molecules in patients with treatment failure, with a good safety profile and encouraging results. We believe that earlier treatment of patients with proven PAIS could improve their clinical outcome.

03

Conditions studied

  • Post-aggressive Immunosuppression
  • Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6
  • Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C

Browse trials for

Keywords

  • Critical care
  • ICU-acquired immune suppression
  • HLA-DR
  • immunity
  • sepsis
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient ≥ 18 years old
  • SOFA score for first 24 hours post-admission ≥ 6
  • Mechanically ventilated at the time of inclusion (non-invasive ventilation (NIV) and high-flow nasal oxygen excluded)
  • mHLA-DR\< 8,000 AB/C measured between the 5th and 10th day after admission to the intensive care unit
  • Patient affiliated to a social security scheme
  • Written from a parent, relative or trusted person. If there is no parent, relative or trusted person, the patient may be included under an emergency procedure and consent to continue will be obtained as soon as possible

Exclusion criteria

Exclusion Criteria:

  • Patient with estimated of less than 3 months
  • Patients with a predicted remaining stay in intensive care \< 72 hours
  • Patients with an expected prolonged duration of mechanical ventilation: comatose or vegetative patients (admission for severe stroke with Glasgow score \< 8, patient resuscitated from an arterial stroke,) patients with tracheotomy for ENT problems, patients suffering from muscular disease (e.g. myopathy), patients on long-term mechanical ventilation
  • Pregnant or breast-feeding women
  • of Imukin ( to interferon gamma-1b or known hypersensitivity to related products, such as another interferon)
  • Patients on therapy, including long-term therapy (>2.5mg/d prednisone equivalent)
  • Patients with preexisting severe hepatic( Grade C cirrhosis ) or preexisting kidney failure requiring dialysis
  • Patient included in another interventional study (excluding RIPH2 cases not involving prolonged mechanical ventilation)
  • People under court protection and protected adults
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    interferon gamma-1b injection

    Patients randomized to the experimental arm will receive : Recombinant human interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

  • Placebo comparator
    Placebo injection

    Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

    Drug: Placebo

Interventions

  • interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

  • DrugPlacebo

    Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

06

What researchers measure

Primary outcomes

  1. number of days alive without mechanical ventilation

    number of days alive without mechanical ventilation on day 28 after randomization or on discharge from intensive care if this occurs before the 28th day

    Time frame: on Day 28 after drug administration

Secondary outcomes

  1. Evaluate the efficacy of IFNy in correcting PAIS-defining biological abnormalities (re-ascension of mHLA-DR above 8,000 AB/C) between patients treated with recombinant interferon gamma 1-b versus placebo

    Evolution of mHLA-DR measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo.

    Time frame: Day 1 to Day 7 and at Day 28 post randomization

  2. Evaluate, depending on the randomization arm, the kinetics of plasma inflammatory parameters between patients treated with recombinant interferon gamma 1-b versus placebo

    Evolution of inflammation markers (IL-1, IL-2, IL-6, IL-8, TNFa, etc.) measured in plasma at Day 0, Day 3 and Day 7, or at discharge from intensive care if it occurs before (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo

    Time frame: Day 0, Day 3 and at Day 7 post randomization

  3. mortality at Day 28 and Day 90 after randomization

    Mortality rate at Day 28 and Day 90 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo

    Time frame: Day 28 and Day 90 after randomization

  4. incidence of nosocomial infections during intensive care unit stay

    The incidence of nosocomial infections during an ICU stay between patients treated with recombinant interferon gamma 1-b versus placebo

    Time frame: from Day 0 to Day 28 (or the discharge from intensive care)

  5. number of days alive whithout antibiotic

    Number of days alive without antibiotic assessed on day 28 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo

    Time frame: Day 28 after drug administration

  6. length of stay in intensive care between patients

    Number of days in intensive care between patients treated with recombinant interferon gamma 1-b versus placebo

    Time frame: from Day 0 to Day 28 (or the discharge from intensive care)

  7. - Compare organ failure score (SOFA) kinetics between patients treated with recombinant interferon gamma 1-b versus placebo

    Kinetics of SOFA score assessed at inclusion and during the 7 days following inclusion between patients treated with recombinant interferon gamma 1-b versus placebo

    Time frame: From inclusion to Day 7

  8. Evaluate, depending on the randomization arm, the transcriptomic profile of circulating peripheral blood mononuclear cells count between patients treated with recombinant interferon gamma 1-b versus placebo

    Evolution of the transcriptomic profile of circulating peripheral blood mononuclear cells (PBMCs) using scRNAseq analysis measured at Day 0, Day 3 and Day 7 or upon discharge from intensive care if this occurs earlier.

    Time frame: Day 0, Day 3 and Day 7 after randomization

  9. Evaluate, depending on the randomization arm the leucocyte count between patients treated with recombinant interferon gamma 1-b versus placebo

    Evolution and kenetics of the leucocyte count measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo

    Time frame: Day 0 to Day 7 and at Day 28 post randomization

07

Study locations

6 of 6 sites recruiting
  • Dr Francois Bruno
    Limoges, 87000, France
    Recruiting
  • Pr Antoine Kimmoun
    Nancy, France
    Recruiting
  • Pr Benjamin Chousterman
    Paris, 75010, France
    Recruiting
  • Pr Constantin Michel
    Paris, 75013, France
    Recruiting
  • Pr Dépret
    Paris, France
    Recruiting
  • Pr Megarbane
    Paris, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2029, 37 months after the start.

Of 18 phase 2/3 interventional studies under Sepsis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 88. This study's planned 37 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 19, 2024
StartActual
Feb 24, 2026
Primary completionEst.
Mar 2029
CompletionEst.
May 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 1 site removed
Show 5 added (5 France)
  • Dr Francois Bruno · Limoges, France
  • Pr Antoine Kimmoun · Nancy, France
  • Pr Benjamin Chousterman · Paris, France
  • Pr Constantin Michel · Paris, France
  • Pr Megarbane · Paris, France
Show 1 removed
  • Dr de Roquetaillade · Paris, France
Nov 12, 2026
Eligibility
1 inclusion criterion added, 1 removed; 2 exclusion criteria added, 3 removed
What changed in the criteria
Inclusion criteria
  • RemovedWritten consent (relative/trusted person)
  • AddedWritten informed consent from a parent, relative or trusted person. If there is no parent, relative or trusted person, the patient may be included under an emergency procedure and consent to continue will be obtained as soon as possible
Exclusion criteria
  • RemovedPatient with pre-existing immunosuppression: solid cancer active or in remission for < 5 years, active hemopathy or in remission for < 5 years, systemic disease (including in the absence of specific treatment), solid organ transplant or marrow allograft patient, patient suffering from a HIV infection
  • RemovedPatients with severe hepatic or renal insufficiency
  • RemovedPatient included in another interventional clinical trial
  • AddedPatients with preexisting severe hepatic( Grade C cirrhosis ) or preexisting kidney failure requiring dialysis
  • AddedPatient included in another interventional study (excluding RIPH2 cases not involving prolonged mechanical ventilation)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    5 sites added, 1 site removed
    Show 5 added (5 France)
    • Dr Francois Bruno · Limoges, France
    • Pr Antoine Kimmoun · Nancy, France
    • Pr Benjamin Chousterman · Paris, France
    • Pr Constantin Michel · Paris, France
    • Pr Megarbane · Paris, France
    Show 1 removed
    • Dr de Roquetaillade · Paris, France
    Eligibility 1 inclusion criterion added, 1 removed; 2 exclusion criteria added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedWritten consent (relative/trusted person)
    • AddedWritten informed consent from a parent, relative or trusted person. If there is no parent, relative or trusted person, the patient may be included under an emergency procedure and consent to continue will be obtained as soon as possible
    Exclusion criteria
    • RemovedPatient with pre-existing immunosuppression: solid cancer active or in remission for < 5 years, active hemopathy or in remission for < 5 years, systemic disease (including in the absence of specific treatment), solid organ transplant or marrow allograft patient, patient suffering from a HIV infection
    • RemovedPatients with severe hepatic or renal insufficiency
    • RemovedPatient included in another interventional clinical trial
    • AddedPatients with preexisting severe hepatic( Grade C cirrhosis ) or preexisting kidney failure requiring dialysis
    • AddedPatient included in another interventional study (excluding RIPH2 cases not involving prolonged mechanical ventilation)
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06694740
Responsible party
Sponsor
First posted
Nov 19, 2024
Start date
Feb 24, 2026
Primary completion
Mar 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Benjamin CHOUSTERMAN, Professor
Contact
benjamin.chousterman@aphp.fr
01 49 95 85 18 ext. +33
Charles De ROQUETAILLADE, MD
Contact
charles.de-roquetaillade@aphp.fr
01 49 95 55 68 ext. +33
Benjamin Chousterman, Professor
study chair · APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion